Revvity

Revvity's management receives a score of 53/100, indicating an acceptable but not outstanding performance. The management team has successfully navigated the complex and challenging divestiture of its Applied, Food, and Enterprise Services business and the subsequent rebranding.

This strategic overhaul, which is reflected in the -17.4% 3-year Revenue CAGR, demonstrates a clear vision to refocus the company on its core diagnostics and life sciences segments.

However, the relatively low TTM Return on Equity of 6.2% and the concerns surrounding capital allocation, evidenced by a score of 46/100, suggest that while management executed a major strategic shift, they still need to prove their ability to consistently translate this new focus into superior financial performance and shareholder returns for the revitalized Revvity.

The market is likely observing how effectively the new strategy drives future growth and profitability.